BioTime Stock Price, News & Analysis (NYSEAMERICAN:BTX)

$2.74 +0.11 (+4.18 %)
(As of 02/25/2018 04:00 PM ET)
Previous Close$2.74
Today's Range$2.61 - $2.75
52-Week Range$2.10 - $3.62
Volume221,453 shs
Average Volume494,049 shs
Market Capitalization$362.15 million
P/E Ratio6.37
Dividend YieldN/A
Beta1.95

About BioTime (NYSEAMERICAN:BTX)

BioTime logoBioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology. Its clinical programs are targeting three primary sectors, aesthetics, ophthalmology and cell/drug delivery. Its facial aesthetics product, Renevia, is a potential treatment for facial lipoatrophy. It is in a pivotal clinical trial in Europe to assess its safety and efficacy in restoring normal skin contours in patients whose subcutaneous fat, or adipose tissue, has been lost due to the use of certain drugs often used to treat patients with human immune virus. OpRegen is its lead product for ophthalmological disorders. It is a suspension of retinal pigment epithelial cells that are derived from pluripotent stem cells.

Receive BTX News and Ratings via Email

Sign-up to receive the latest news and ratings for BTX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorBio Therapeutic Drugs
SymbolNYSEAMERICAN:BTX
CUSIP09066L10
Phone+1-510-5213390

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio6.37209302325581
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPS$0.43
Net IncomeN/A
Net Margins828.55%
Return on Equity30.68%
Return on Assets27.02%

Miscellaneous

EmployeesN/A
Outstanding Shares126,870,000

BioTime (NYSEAMERICAN:BTX) Frequently Asked Questions

What is BioTime's stock symbol?

BioTime trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "BTX."

How were BioTime's earnings last quarter?

BioTime, Inc. (NYSEAMERICAN:BTX) issued its quarterly earnings data on Tuesday, August, 9th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.06. The biotechnology company earned $1.27 million during the quarter, compared to analyst estimates of $1.75 million. BioTime had a return on equity of 30.68% and a net margin of 828.55%. View BioTime's Earnings History.

When will BioTime make its next earnings announcement?

BioTime is scheduled to release their next quarterly earnings announcement on Wednesday, March, 14th 2018. View Earnings Estimates for BioTime.

Where is BioTime's stock going? Where will BioTime's stock price be in 2018?

3 analysts have issued 12 month price targets for BioTime's stock. Their predictions range from $6.00 to $8.00. On average, they expect BioTime's share price to reach $6.83 in the next year. View Analyst Ratings for BioTime.

Are investors shorting BioTime?

BioTime saw a increase in short interest in January. As of January 31st, there was short interest totalling 6,928,298 shares, an increase of 1.7% from the January 12th total of 6,810,166 shares. Based on an average daily trading volume, of 611,671 shares, the short-interest ratio is presently 11.3 days. Approximately 5.6% of the shares of the company are sold short.

Who are some of BioTime's key competitors?

Who are BioTime's key executives?

BioTime's management team includes the folowing people:

  • Alfred D. Kingsley, Chairman of the Board (Age 74)
  • Aditya P. Mohanty, President, Co-Chief Executive Officer, Director (Age 50)
  • Michael D. West Ph.D., Co-Chief Executive Officer, Director (Age 63)
  • Russell L. Skibsted, Chief Financial Officer (Age 58)
  • Judith Segall, Vice President, Secretary (Age 62)
  • Stephana Eilene Patton Ph.D., J.D., General Counsel (Age 46)
  • Deborah J. Andrews, Independent Director (Age 59)
  • Neal C. Bradsher, Independent Director (Age 51)
  • Stephen C. Farrell CPA, Independent Director (Age 52)
  • Michael H. Mulroy, Independent Director (Age 51)

Who owns BioTime stock?

BioTime's stock is owned by a variety of of retail and institutional investors. Top institutional investors include AXA (1.81%), Artal Group S.A. (1.23%), Renaissance Technologies LLC (0.94%), Geode Capital Management LLC (0.87%), Bank of New York Mellon Corp (0.52%) and Destination Wealth Management (0.41%). Company insiders that own BioTime stock include Aditya P Mohanty, Broadwood Partners Lp, Broadwood Partners, LP, Deborah J Andrews, Michael D West and Russell Skibsted. View Institutional Ownership Trends for BioTime.

Who sold BioTime stock? Who is selling BioTime stock?

BioTime's stock was sold by a variety of institutional investors in the last quarter, including Destination Wealth Management. View Insider Buying and Selling for BioTime.

Who bought BioTime stock? Who is buying BioTime stock?

BioTime's stock was acquired by a variety of institutional investors in the last quarter, including AXA, Renaissance Technologies LLC, Artal Group S.A., Bank of New York Mellon Corp, Granite Point Capital Management L.P., Two Sigma Investments LP, Millennium Management LLC and Virtu Financial LLC. Company insiders that have bought BioTime stock in the last two years include Aditya P Mohanty, Broadwood Partners Lp, Broadwood Partners, LP, Deborah J Andrews, Michael D West and Russell Skibsted. View Insider Buying and Selling for BioTime.

How do I buy BioTime stock?

Shares of BioTime can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioTime's stock price today?

One share of BioTime stock can currently be purchased for approximately $2.74.

How big of a company is BioTime?

BioTime has a market capitalization of $362.15 million.

How can I contact BioTime?

BioTime's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at +1-510-5213390.


MarketBeat Community Rating for BioTime (BTX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  108 (Vote Outperform)
Underperform Votes:  92 (Vote Underperform)
Total Votes:  200
MarketBeat's community ratings are surveys of what our community members think about BioTime and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

BioTime (NYSEAMERICAN:BTX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.83$6.25$6.25$6.25
Price Target Upside: 124.04% upside106.27% upside106.27% upside106.27% upside

BioTime (NYSEAMERICAN:BTX) Consensus Price Target History

Price Target History for BioTime (NYSEAMERICAN:BTX)

BioTime (NYSEAMERICAN:BTX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
2/2/2018Lake Street CapitalInitiated CoverageBuy -> Buy$8.00View Rating Details
6/19/2017Ladenburg Thalmann Financial ServicesReiterated RatingBuy$6.00 -> $6.50View Rating Details
3/31/2017Raymond James FinancialInitiated CoverageOutperform -> Outperform$6.00View Rating Details
4/7/2016Chardan CapitalInitiated CoverageBuyView Rating Details
4/2/2016OppenheimerReiterated RatingBuyView Rating Details
(Data available from 2/25/2016 forward)

Earnings

BioTime (NYSEAMERICAN:BTX) Earnings History and Estimates Chart

Earnings by Quarter for BioTime (NYSEAMERICAN:BTX)

BioTime (NYSEAMERICAN BTX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/14/2018($0.07)N/AView Earnings Details
11/9/2017Q3 2017($0.09)($0.05)$1.69 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.09)($0.05)$0.38 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.09)($0.08)$0.39 millionViewN/AView Earnings Details
11/3/2016Q316($0.14)($0.08)$1.46 million$1.50 millionViewN/AView Earnings Details
8/9/2016Q216($0.17)($0.11)$1.75 million$1.27 millionViewN/AView Earnings Details
5/10/2016Q116($0.14)($0.19)$1.43 million$2.10 millionViewN/AView Earnings Details
3/15/2016Q4($0.17)($0.16)$1.31 millionViewN/AView Earnings Details
11/9/2015Q3 2015($0.18)$2.31 millionViewN/AView Earnings Details
8/10/2015Q2($0.12)$2.01 millionViewN/AView Earnings Details
5/11/2015Q115($0.13)$1.10 million$1.30 millionViewN/AView Earnings Details
3/11/2015Q4 2014($0.14)$1.89 millionViewN/AView Earnings Details
11/10/2014Q314($0.12)$1.20 millionViewN/AView Earnings Details
8/12/2014Q214($0.16)$362.25 million$300.08 millionViewN/AView Earnings Details
5/12/2014Q114($0.14)$0.61 million$1.07 millionViewN/AView Earnings Details
3/17/2014Q4 2013($0.35)$1.89 millionViewN/AView Earnings Details
11/12/2013Q3($0.16)$0.71 millionViewN/AView Earnings Details
8/9/2013Q2 2013($0.14)$1.22 millionViewN/AView Earnings Details
5/10/2013Q1 2013($0.15)$0.61 millionViewN/AView Earnings Details
3/18/2013Q412($0.12)$1.70 million$1.20 millionViewN/AView Earnings Details
11/9/2012Q3 2012($0.10)ViewN/AView Earnings Details
8/9/2012Q2 2012($0.11)ViewN/AView Earnings Details
5/10/2012Q1 2012($0.10)ViewN/AView Earnings Details
3/14/2012Q4 2011($0.10)ViewN/AView Earnings Details
11/8/2011Q3 2011($0.08)ViewN/AView Earnings Details
8/9/2011Q2 2011($0.09)ViewN/AView Earnings Details
5/5/2011Q1 2011($0.07)ViewN/AView Earnings Details
3/15/2011Q4 2010($0.06)ViewN/AView Earnings Details
11/15/2010Q3 2010($0.06)ViewN/AView Earnings Details
8/16/2010Q2 2010($0.06)ViewN/AView Earnings Details
5/5/2010Q1 2010($0.04)ViewN/AView Earnings Details
3/10/2010Q4 2009$0.06ViewN/AView Earnings Details
11/24/2009Q3 2009($0.11)ViewN/AView Earnings Details
3/30/2009Q4 2008($0.07)ViewN/AView Earnings Details
5/19/2008Q1 2008($0.02)ViewN/AView Earnings Details
4/15/2008Q4 2007($0.01)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

BioTime (NYSEAMERICAN:BTX) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for BioTime (NYSEAMERICAN:BTX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

BioTime (NYSEAMERICAN BTX) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for BioTime (NYSEAMERICAN:BTX)
Institutional Ownership by Quarter for BioTime (NYSEAMERICAN:BTX)

BioTime (NYSEAMERICAN BTX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/13/2017Broadwood Partners, L.P.DirectorBuy2,692,307$2.60$6,999,998.20View SEC Filing  
8/23/2017Russell SkibstedCFOBuy2,000$2.64$5,280.00View SEC Filing  
8/22/2017Broadwood Partners, L.P.DirectorBuy10,000$2.60$26,000.00View SEC Filing  
8/22/2017Michael D. WestCEOBuy2,000$2.60$5,200.00View SEC Filing  
8/21/2017Aditya P. MohantyCEOBuy7,500$2.50$18,750.00View SEC Filing  
8/21/2017Deborah J AndrewsDirectorBuy2,396$2.50$5,990.008,396View SEC Filing  
7/31/2017Broadwood Partners, L.P.DirectorBuy150,000$2.80$420,000.00View SEC Filing  
6/16/2017Deborah J AndrewsDirectorBuy2,000$2.95$5,900.006,000View SEC Filing  
5/16/2017Deborah J AndrewsDirectorBuy2,000$3.21$6,420.004,000View SEC Filing  
2/15/2017Broadwood Partners, L.P.DirectorBuy2,222,222$2.70$5,999,999.40View SEC Filing  
6/21/2016Broadwood Partners LpDirectorBuy2,732,636$2.39$6,531,000.04View SEC Filing  
1/20/2016Broadwood Partners LpDirectorBuy300,000$2.35$705,000.00View SEC Filing  
11/6/2015Alfred D KingsleyInsiderSell100,000$3.83$383,000.005,938,055View SEC Filing  
11/6/2015Stephen C FarrellDirectorBuy50,000$3.83$191,500.0097,450View SEC Filing  
8/26/2015Deborah J AndrewsDirectorBuy2,000$2.82$5,640.002,000View SEC Filing  
8/18/2015Stephen Lahue CarttDirectorBuy75,000$2.80$210,000.00View SEC Filing  
10/8/2014David SchlachetDirectorBuy32,050$3.12$99,996.00View SEC Filing  
7/22/2014Broadwood Partners LpDirectorBuy370,000$2.65$980,500.00View SEC Filing  
7/22/2014Michael D WestCEOSell270,000$2.65$715,500.00View SEC Filing  
7/22/2014Robert PeabodyCFOSell100,000$2.65$265,000.00View SEC Filing  
6/17/2014William P Phd TewInsiderSell30,000$3.07$92,100.00View SEC Filing  
6/16/2014Broadwood Partners LpDirectorBuy1,000,000$2.50$2,500,000.00View SEC Filing  
5/16/2014Broadwood Partners LpDirectorBuy300,000$2.45$735,000.00View SEC Filing  
5/8/2014Broadwood Partners LpDirectorBuy300,000$2.44$732,000.00View SEC Filing  
5/1/2014Broadwood Partners LpDirectorBuy2,000,000$2.52$5,040,000.00View SEC Filing  
2/25/2014Broadwood Partners LpDirectorBuy500,000$3.74$1,870,000.00View SEC Filing  
12/30/2013Neal C BradsherDirectorBuy300,042$3.51$1,053,147.42View SEC Filing  
11/20/2013William P Phd TewInsiderSell13,860$3.76$52,113.60View SEC Filing  
9/12/2013Stephen C FarrellDirectorBuy11,213$3.89$43,618.57View SEC Filing  
8/20/2013Stephen C FarrellDirectorBuy4,187$3.65$15,282.55View SEC Filing  
8/12/2013Eschenbach Andrew C VonDirectorBuy3,000$3.69$11,070.00View SEC Filing  
3/28/2013Broadwood Partners LpDirectorBuy200,000$3.81$762,000.00View SEC Filing  
11/15/2012Broadwood Partners LpDirectorBuy344,828$2.90$1,000,001.20View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

BioTime (NYSEAMERICAN BTX) News Headlines

Source:
DateHeadline
BioTime Appoints Cavan Redmond to Its Board of Directors - Business Wire (press release)BioTime Appoints Cavan Redmond to Its Board of Directors - Business Wire (press release)
www.businesswire.com - February 22 at 7:27 AM
BioTime Appoints Cavan Redmond to Its Board of DirectorsBioTime Appoints Cavan Redmond to Its Board of Directors
finance.yahoo.com - February 22 at 7:27 AM
BioTime May Very Well Be The Wayne Gretzky Of Clinical Stage Biotech Companies - Seeking AlphaBioTime May Very Well Be The Wayne Gretzky Of Clinical Stage Biotech Companies - Seeking Alpha
seekingalpha.com - February 21 at 3:22 PM
and Vision Restoration Programs to Be Presented at ARVO 2018 - Business Wire (press release)and Vision Restoration Programs to Be Presented at ARVO 2018 - Business Wire (press release)
www.businesswire.com - February 15 at 3:19 PM
Data from BioTimes OpRegen® and Vision Restoration Programs to Be Presented at ARVO 2018Data from BioTime's OpRegen® and Vision Restoration Programs to Be Presented at ARVO 2018
finance.yahoo.com - February 15 at 3:19 PM
BioTime, Inc. (BTX) Short Interest UpdateBioTime, Inc. (BTX) Short Interest Update
www.americanbankingnews.com - February 9 at 8:06 PM
BioTime to Participate at the BIO CEO and Investor Conference in New York, February 12 - Business Wire (press release)BioTime to Participate at the BIO CEO and Investor Conference in New York, February 12 - Business Wire (press release)
www.businesswire.com - February 7 at 3:15 PM
BioTime to Participate at the BIO CEO and Investor Conference in New York, February 12th and 13th 2018BioTime to Participate at the BIO CEO and Investor Conference in New York, February 12th and 13th 2018
finance.yahoo.com - February 7 at 3:15 PM
BioTime, Inc. (BTX) Receives Consensus Rating of "Hold" from BrokeragesBioTime, Inc. (BTX) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - February 2 at 3:44 PM
BioTime (BTX) Coverage Initiated by Analysts at Lake Street CapitalBioTime (BTX) Coverage Initiated by Analysts at Lake Street Capital
www.americanbankingnews.com - February 2 at 11:40 AM
Renevia® Data From the Successful Pivotal Trial to Be Presented at the IMCAS ConferenceRenevia® Data From the Successful Pivotal Trial to Be Presented at the IMCAS Conference
finance.yahoo.com - January 29 at 3:13 PM
BioTime, Inc. (BTX) Short Interest Up 1.4% in JanuaryBioTime, Inc. (BTX) Short Interest Up 1.4% in January
www.americanbankingnews.com - January 24 at 6:08 PM
BioTime Announces Clinical and Corporate Milestone Targets for 2018 - Business Wire (press release)BioTime Announces Clinical and Corporate Milestone Targets for 2018 - Business Wire (press release)
www.businesswire.com - January 23 at 3:17 PM
BioTime to Present at the Noble Capital Markets 14th Annual ... - Business Wire (press release)BioTime to Present at the Noble Capital Markets 14th Annual ... - Business Wire (press release)
www.businesswire.com - January 23 at 3:17 PM
BioTime to Present at the Noble Capital Markets 14th Annual Institutional Investor Conference in Fort Lauderdale, January 29, 2018BioTime to Present at the Noble Capital Markets 14th Annual Institutional Investor Conference in Fort Lauderdale, January 29, 2018
finance.yahoo.com - January 23 at 8:28 AM
AgeX CEO Michael D. West to Present in Plenary Session at The World Stem Cell Summit on “Stem Cell Innovations ... - Business Wire (press release)AgeX CEO Michael D. West to Present in Plenary Session at The World Stem Cell Summit on “Stem Cell Innovations ... - Business Wire (press release)
www.businesswire.com - January 19 at 10:47 AM
BioTime (BTX) Announces Issuance of 41 New Patents - StreetInsider.comBioTime (BTX) Announces Issuance of 41 New Patents - StreetInsider.com
www.streetinsider.com - January 19 at 10:47 AM
AgeX CEO Michael D. West to Present in Plenary Session at The World Stem Cell Summit on “Stem Cell Innovations That Will Change the World”AgeX CEO Michael D. West to Present in Plenary Session at The World Stem Cell Summit on “Stem Cell Innovations That Will Change the World”
finance.yahoo.com - January 18 at 10:33 AM
BioTime (BTX) Announces Issuance of 41 New PatentsBioTime (BTX) Announces Issuance of 41 New Patents
www.streetinsider.com - January 17 at 9:30 AM
BioTime Announces Issuance of 41 New Patents to Expand and Bolster Its Patent EstateBioTime Announces Issuance of 41 New Patents to Expand and Bolster Its Patent Estate
finance.yahoo.com - January 17 at 9:30 AM
BioTime (BTX) Downgraded by Zacks Investment ResearchBioTime (BTX) Downgraded by Zacks Investment Research
www.americanbankingnews.com - January 12 at 5:54 PM
AgeX Therapeutics to Present at Biotech Showcase Annual ConferenceAgeX Therapeutics to Present at Biotech Showcase Annual Conference
finance.yahoo.com - January 5 at 4:57 PM
BioTime (BTX) Publishes Study on Identification of Genes Implicated in Tissue Regeneration and Cancer - StreetInsider.comBioTime (BTX) Publishes Study on Identification of Genes Implicated in Tissue Regeneration and Cancer - StreetInsider.com
www.streetinsider.com - January 3 at 5:14 PM
AgeX Therapeutics Identifies Genes Implicated in Tissue Regeneration and CancerAgeX Therapeutics Identifies Genes Implicated in Tissue Regeneration and Cancer
finance.yahoo.com - January 2 at 9:37 AM
ETFs with exposure to BioTime, Inc. : December 29, 2017ETFs with exposure to BioTime, Inc. : December 29, 2017
finance.yahoo.com - December 29 at 5:07 PM
Short Interest in BioTime, Inc. (BTX) Declines By 2.5%Short Interest in BioTime, Inc. (BTX) Declines By 2.5%
www.americanbankingnews.com - December 28 at 1:26 AM
BioTime (BTX) Lowered to Hold at Zacks Investment ResearchBioTime (BTX) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - December 22 at 9:04 PM
ETFs with exposure to BioTime, Inc. : December 18, 2017ETFs with exposure to BioTime, Inc. : December 18, 2017
finance.yahoo.com - December 18 at 5:09 PM
BioTime, Inc. (BTX) Short Interest Up 0.7% in NovemberBioTime, Inc. (BTX) Short Interest Up 0.7% in November
www.americanbankingnews.com - December 11 at 7:58 PM
ETFs with exposure to BioTime, Inc. : December 7, 2017ETFs with exposure to BioTime, Inc. : December 7, 2017
finance.yahoo.com - December 7 at 5:36 PM
BioTime (BTX) Presented Detailed Data on Successful Pivotal Trial of Renevia in EuripeBioTime (BTX) Presented Detailed Data on Successful Pivotal Trial of Renevia in Euripe
www.streetinsider.com - December 5 at 10:21 AM
BioTime, Inc. :BTX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 5, 2017BioTime, Inc. :BTX-US: Earnings Analysis: Q3, 2017 By the Numbers : December 5, 2017
finance.yahoo.com - December 5 at 10:21 AM
Zacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, Signal Genetics and StratasysZacks.com highlights: BioTime, Ritter Pharmaceuticals, Organovo Holdings, Signal Genetics and Stratasys
finance.yahoo.com - December 5 at 10:21 AM
BioTime (BTX) Presented Detailed Data on Successful Pivotal Trial of Renevia in Euripe - StreetInsider.comBioTime (BTX) Presented Detailed Data on Successful Pivotal Trial of Renevia in Euripe - StreetInsider.com
www.streetinsider.com - December 4 at 5:11 PM
AgeX Therapeutics CEO Michael D. West to Participate in Roundtable Panel on the Path Forward for Stem Cell Therapy at Termis Americas’ Annual Conference on Tissue Engineering ...AgeX Therapeutics CEO Michael D. West to Participate in Roundtable Panel on the Path Forward for Stem Cell Therapy at Termis Americas’ Annual Conference on Tissue Engineering ...
www.businesswire.com - December 4 at 9:36 AM
AgeX Therapeutics CEO Michael D. West to Participate in Roundtable Panel on the Path Forward for Stem Cell Therapy at Termis Americas’ Annual Conference on Tissue Engineering & Regenerative Medicine, December 6 in Charlotte, NCAgeX Therapeutics CEO Michael D. West to Participate in Roundtable Panel on the Path Forward for Stem Cell Therapy at Termis Americas’ Annual Conference on Tissue Engineering & Regenerative Medicine, December 6 in Charlotte, NC
finance.yahoo.com - December 4 at 9:36 AM
Zacks.com featured highlights: Akari Therapeutics, Joint, Tailored Brands, Ardelyx and BioTimeZacks.com featured highlights: Akari Therapeutics, Joint, Tailored Brands, Ardelyx and BioTime
finance.yahoo.com - December 1 at 5:00 PM
Data from BioTime’s Renevia ® Program to Be Presented at IFATS ConferenceData from BioTime’s Renevia ® Program to Be Presented at IFATS Conference
www.businesswire.com - November 30 at 10:08 AM
Data from BioTime’s Renevia® Program to Be Presented at IFATS ConferenceData from BioTime’s Renevia® Program to Be Presented at IFATS Conference
finance.yahoo.com - November 30 at 10:08 AM
5 Affordable Breakout Stocks Offering Excellent Returns5 Affordable Breakout Stocks Offering Excellent Returns
finance.yahoo.com - November 30 at 10:08 AM
BioTime, Inc. is trading above its 50 day moving average : BTX-US : November 29, 2017BioTime, Inc. is trading above its 50 day moving average : BTX-US : November 29, 2017
finance.yahoo.com - November 29 at 9:45 AM
BioTime, Inc. – Value Analysis (NYSE AMERICAN:BTX) : November 28, 2017BioTime, Inc. – Value Analysis (NYSE AMERICAN:BTX) : November 28, 2017
finance.yahoo.com - November 28 at 5:12 PM
BioTime, Inc. (BTX) Short Interest Up 1.3% in NovemberBioTime, Inc. (BTX) Short Interest Up 1.3% in November
www.americanbankingnews.com - November 27 at 7:48 PM
BioTime, Inc. breached its 50 day moving average in a Bullish Manner : BTX-US : November 27, 2017BioTime, Inc. breached its 50 day moving average in a Bullish Manner : BTX-US : November 27, 2017
finance.yahoo.com - November 27 at 6:26 PM
BioTime (BTX) Announces Updated OpRegen® Phase I/IIa Trial Data - StreetInsider.comBioTime (BTX) Announces Updated OpRegen® Phase I/IIa Trial Data - StreetInsider.com
www.streetinsider.com - November 16 at 10:13 PM
BioTime, Inc.: Trading close to its 50 day moving average. Good buy?BioTime, Inc.: Trading close to its 50 day moving average. Good buy?
finance.yahoo.com - November 16 at 12:14 PM
BioTime, Inc. (BTX) Lifted to Buy at Zacks Investment ResearchBioTime, Inc. (BTX) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - November 15 at 5:06 PM

SEC Filings

BioTime (NYSEAMERICAN:BTX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

BioTime (NYSEAMERICAN:BTX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

BioTime (NYSEAMERICAN BTX) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.